| Literature DB >> 25805427 |
Shintaro Michishita1, Seung Jin Kim2, Kenzo Shimazu1, Yoshiaki Sota1, Yasuto Naoi1, Naomi Maruyama1, Naofumi Kagara1, Masafumi Shimoda1, Atsushi Shimomura1, Shinzaburo Noguchi1.
Abstract
The purpose of this study was to evaluate whether the baseline breast MRI findings would be useful for the prediction for pathological complete response (pCR) by breast cancer patients to neoadjuvant chemotherapy. Primary breast cancer patients (stage II-III) preoperatively treated with sequential paclitaxel (12 cycles) and fluorouracil, epirubicin, and cyclophosphamide (4 cycles), followed by surgery were retrospectively enrolled, and 229 patients were eligible. Before chemotherapy, breast MRI studies were performed. Breast tumors were dichotomized into round + oval and irregular types based on MRI morphology. The round + oval tumors showed a significantly higher pCR rate than the irregular tumors (42.0% vs 17.3%; P < 0.001). In addition, PAM50 analysis revealed that basal and HER2-enriched tumors were significantly more prevalent among round + oval than irregular type tumors (P = 0.015). Baseline MRI morphology appears to be a significant predictor for pCR. The higher rate of the basal and HER2-enriched tumors among the round + oval tumors may explain their better chemo-sensitivity.Entities:
Keywords: Intrinsic subtype; MRI morphology; Neoadjuvant chemotherapy; Predictor; pCR
Mesh：
Substances：
Year: 2015 PMID： 25805427 DOI： 10.1016/j.breast.2015.01.001
Source DB: PubMed Journal: Breast ISSN： 0960-9776 Impact factor: 4.380